A Pilot Phase I Randomized Study to evaluate Innate Immune Activation predictors of sustained viral control in HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption after the administration of Pegylated Interferon Alpha 2b in Combination with Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074

Recruiting
99 years or below
All
Phase 1
12 participants needed
1 Location

Brief description of study

Our pilot study will evaluate whether the activation of antiviral innate mechanisms by administration of Pegylated Interferon alpha 2b (peg-IFN-2b) when combined with two broadly neutralizing antibodies (3BNC117 and 10-1074) in HIV positive participants with well controlled viral replication can result in viral control in the absence of ART or immune based therapy during a monitored analytical treatment interruption.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 12 Dec 2019. Study ID: 833816

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.